VASCULITIS CLINICAL RESEARCH CONSORTIUM (VCRC) STUDY OF TAKAYASU'S ARTERITIS

血管炎临床研究联盟 (VCRC) 对 TAKAYASU 动脉炎的研究

• 批准号: 7608195
• 负责人: Carol Langford
• 金额: $ 0.05万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608195
• 关键词: Biological Markers; Blood; Clinical Research; Cohort Studies; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Disease; Evaluation; Funding; Grant; Institution; Longitudinal Studies; Measures; Patients; Persons; Physicians; Purpose; Research; Research Personnel; Resources; Source; Specimen; Takayasu' s Arteritis; Time; United States National Institutes of Health; Urine; Vasculitis; follow-up; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this longitudinal study is to develop new biomarkers for Takayasu's arteritis (TAK), a form of idiopathic vasculitis, for the purposes of diagnosis, disease activity measdurement, disease damage assessment, determination of disease state and evaluation of treatment response. It is often difficult for both patients and physicians to determine how "active" a person's TAK is at any given time, yet it is critically important to determine disease activity in order to properly treat this disease. Discovering new biological markers of disease activity will serve one or more of the following uses: measure the amount of disease occuring at any given time, predict what types of problems patients are at srisk for in order to help choose the best therapy, and predict whether patients will respond to specific treatments. Subject's blood and urine specimens will be analyzed for biomarkers. A longitudinal observations cohort study of 160 patients followed for up to five years will be implemented.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项纵向研究的主要目的是开发高安动脉炎（TAK）（一种特发性血管炎）的新生物标志物，用于诊断、疾病活动测量、疾病损害评估、疾病状态确定和治疗反应评估。 对于患者和医生来说，通常很难确定一个人的 TAK 在任何给定时间的“活跃程度”，但确定疾病活动性以便正确治疗这种疾病至关重要。 发现疾病活动的新生物标志物将具有以下一种或多种用途：测量在任何给定时间发生的疾病数量，预测患者面临哪些类型的问题以帮助选择最佳治疗，以及预测患者是否会对特定治疗产生反应。 将分析受试者的血液和尿液样本中的生物标志物。 将对 160 名患者进行长达五年的纵向观察队列研究。